Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En observasjonsstudie for å vurdere effektiviteten og sikkerheten til Cemiplimab hos pasienter med avansert ikke-småcellet lungekreft (NSCLC) i rutinemessige kliniske praksismiljøer i Europa (CEMI-LUNG) (CEMI-LUNG)

29. oktober 2026 oppdatert av: Regeneron Pharmaceuticals

An Observational Study to Assess the Effectiveness and Safety of Cemiplimab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG)

This study is focused on patients with non-small cell lung cancer (NSCLC) and have been prescribed a cemiplimab (Libtayo®) based treatment regimen under standard care.

The goal of this study is to learn more about the use, benefits, and safety of cemiplimab based treatment regimens in participants with NSCLC.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Detaljert beskrivelse

Originally registered as OBS17104 by Sanofi; transitioned to REGN 05Jul2023.

The recruitment period will be 48 months. Data will be collected during routine clinical visits approximately every three months while the patient is on cemiplimab treatment and then approximately every six months for up to 24 months after cemiplimab discontinuation. Patients will be followed from cemiplimab treatment initiation until death, loss to follow-up, study withdrawal, or to the end of the study period (72 months after study launch), whichever occurs first.

Studietype

Observasjonsmessig

Registrering (Faktiske)

509

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Angers, Frankrike, 49000
        • Centre Hospitalier Universitaire Angers
      • Clermont-Ferrand, Frankrike, 63003
        • Center Hospitalier Universitaire (CHU) of Clermont
      • Le Mans, Frankrike, 72037
        • Centre Hospitalier - Le mans
      • Paris, Frankrike, 75020
        • Hopital Tenon
    • Alsace
      • Mulhouse, Alsace, Frankrike, 68100
        • Le Groupe Hospitalier de la Region de Mulhouse et Sud Alsace, Emile Muller Hospital
    • Bas-Rhin
      • Strasbourg, Bas-Rhin, Frankrike, 67000
        • Hopitaux Universitaires de Strasbourg
    • Bouches-du-Rhône
      • Marseille, Bouches-du-Rhône, Frankrike, 13915
        • APHM - Hopital Nord
    • Vaucluse
      • Avignon, Vaucluse, Frankrike, 84918
        • Sainte Catherine Institut du Cancer Avignon Provence
    • Vienne
      • Poitiers, Vienne, Frankrike, 86021
        • Centre Hospitalier Universitaire (CHU) de Poitiers
      • Catania, Italia, 95123
        • AO Universitaria Policlinico Vittorio Emanuele
      • Milan, Italia, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Modena, Italia, 41124
        • Azienda Ospedaliero-Universitaria di Modena
      • Naples, Italia, 80131
        • Istituto Nazionale Tumori IRCCS Fondazione G Pascale
      • Naples, Italia, 80131
        • AORN dei Colli
      • Pavia, Italia, 27100
        • Fondazione IRCCS Policlinico San Matteo
      • Taranto, Italia, 74010
        • Azienda Sanitaria Locale (ASL) Taranto
    • Catania
      • Misterbianco, Catania, Italia, 95065
        • Humanitas Istituto Clinico Catanese
    • Firenze
      • Florence, Firenze, Italia, 50134
        • AOU Careggi
    • Friuli Venezia Giulia
      • Udine, Friuli Venezia Giulia, Italia, 33100
        • Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) Santa Maria della Misericordia
    • Milan
      • Rozzano, Milan, Italia, 20089
        • IRCCS Humanitas Research Hospital
    • Piedmont
      • Orbassano, Piedmont, Italia, 10043
        • San Luigi Gonzaga University Hospital
    • Tuscany
      • Pisa, Tuscany, Italia, 56126
        • Ospedale Di Cisanello Azienda Ospedaliero Universitaria
      • Almería, Spania, 04009
        • Hospital Torrecardenas
      • Jaén, Spania, 23007
        • University Hospital of Jaen
      • Lleida, Spania, 25198
        • Hospital Arnau de Vilanova
      • Santa Cruz de Tenerife, Spania, 38010
        • Hospital Universitario Nuestra Senora de Candelaria
      • Tarragona, Spania, 43204
        • Hospital Universitari Sant Joan de Reus
    • Andalusia
      • Málaga, Andalusia, Spania, 29010
        • Hospital Universitario Virgen De La Victoria Malaga
    • Barcelona
      • Sabadell, Barcelona, Spania, 08208
        • Parc Tauli Sabadell Hospital Universitari
    • Cadiz
      • Jerez de la Frontera, Cadiz, Spania, 11407
        • Hospital Universitario De Jerez
    • Castellon
      • Castellon, Castellon, Spania, 12002
        • Consorcio Hospitalario Provincial de Castellon
    • Galicia
      • Ferrol, Galicia, Spania, 15405
        • Complejo Hospitalario Universitario de Ferrol - Hospital Naval
      • Vigo, Galicia, Spania, 36204
        • Hospital Universitario Alvaro Cunqueiro
      • Berlin, Tyskland, 14089
        • Gemeinschaftskrankenhaus Havelhoehe
      • Dortmund, Tyskland, 44263
        • Gesellschaft fur Onkologische Studien Dortmund mbH (Gefos)
      • Halle, Tyskland, 06120
        • Krankenhaus Martha-Maria Halle-Doelau gGmbH
    • Baden-Wurttemberg
      • Konstanz, Baden-Wurttemberg, Tyskland, 78464
        • Klinikum Konstanz
    • Bavaria
      • München, Bavaria, Tyskland, 81925
        • Staedtisches Klinikum Muenchen Bogenhausen
      • Nuremberg, Bavaria, Tyskland, 90419
        • Nuremberg Hospital, Campus North
    • Georgsmarienhuette
      • Georgsmarienhütte, Georgsmarienhuette, Tyskland, 49124
        • Franziskus Hospital Harderberg
    • Lower Saxony
      • Rotenburg (Wümme), Lower Saxony, Tyskland, 27356
        • Agaplesion Diakonieklinikum Rotenburg
    • North Rhine-Westphalia
      • Münster, North Rhine-Westphalia, Tyskland, 48145
        • St. Franziskus Hospital Münster
      • Troisdorf, North Rhine-Westphalia, Tyskland, 53840
        • Haematologisch Onkologische Schwerpunktpraxis - Troisdorf
    • Saxony
      • Leipzig, Saxony, Tyskland, 4347
        • Pneumologische Praxis PD Dr. Med Christian Gessner
      • Salzburg, Østerrike, 5020
        • Salzburger Landeskliniken (SALK)
    • Carinthia
      • Klagenfurt, Carinthia, Østerrike, 9020
        • Klinikum Klagenfurt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

The source population for this study will be patients with either locally advanced NSCLC not suitable for definitive chemoradiation or metastatic NSCLC and who are initiating a cemiplimab-based regimen of treatment as part of routine clinical practice at the time of study enrollment. The study will aim to enroll approximately 500 adult patients from up to 50 sites across Europe.

Beskrivelse

Key Inclusion Criteria:

  1. At least 18 years of age at the time of cemiplimab treatment initiation
  2. Has been diagnosed with histologically or cytologically documented squamous or non-squamous NSCLC
  3. Prescribed a cemiplimab-based regimen as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the Summary of Product Characteristics (SmPC).
  4. Can understand and complete the study-related questionnaires
  5. Must be legally capable of providing written consent for participation in the study and have signed informed consent prior to any study activities

Key Exclusion Criteria:

  1. Has received cemiplimab prior to enrollment
  2. Has uncontrolled autoimmune disease
  3. Has a contraindication to cemiplimab as noted in the local SmPC
  4. Is concurrently participating in any other study of an investigational drug or procedure
  5. Has cognitive impairment or other medical condition that, in the opinion of the investigator, would interfere with the ability to complete the study-related questionnaires

NOTE: Other protocol-defined inclusion/exclusion criteria apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Cohort 1

Cemiplimab monotherapy

solution for injection via intravenous (IV) infusion

Andre navn:
  • SAR439684- Libtayo
Cohort 2

Cemiplimab in combination with platinum-based chemotherapy

solution for injection via intravenous (IV) infusion

Andre navn:
  • SAR439684- Libtayo

IV administration

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall survival (OS)
Tidsramme: Up to 72 months

Date and primary cause of death

Up to 72 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Response Rate (ORR)
Tidsramme: Up to 72 months

Defined as the proportion of patients with a complete response or partial as the physician-reported best overall response.

Up to 72 months
Duration of Response (DoR)
Tidsramme: Up to 72 months

Defined among responders (patients with a complete response or partial response) as the time from the date of the first response after cemiplimab treatment initiation until the first date of disease progression or death due to any cause.

Up to 72 months
Time to Response (TTR)
Tidsramme: Up to 72 months

Defined as the time from the first cemiplimab dose until the date of first response observed for that patient. Patients who die during the study will be censored using the date of the last valid disease assessment).

Up to 72 months
Progression-Free Survival (PFS)
Tidsramme: Up to 72 months

Defined as the time from the first dose of cemiplimab until the date of the first documented tumour progression or death due to any cause.

Up to 72 months
Time to first subsequent anti-NSCLC treatment (TTST)
Tidsramme: Up to 72 months

Defined as the time from the first cemiplimab dose until the date of the first subsequent anti-NSCLC treatment.

Up to 72 months
Incidence of treatment-related adverse events (TR-AEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Tidsramme: Up to 72 months

Number of patients with treatment related adverse events occurring during treatment

Up to 72 months
Incidence of treatment-related serious adverse events (TR-SAEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Tidsramme: Up to 72 months

Number of patients with serious treatment related adverse events occurring during treatment

Up to 72 months
Incidence and severity of immune-mediated adverse events (imAEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Tidsramme: Up to 72 months

Number of patients with immune-mediated adverse events and serious immune-mediated adverse events occurring during treatment

Up to 72 months
Incidence and severity of infusion related reactions (IRRs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Tidsramme: Up to 72 months

Number of patients with infusion related reactions and serious infusion related reactions adverse events occurring during treatment

Up to 72 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

26. oktober 2022

Primær fullføring (Antatt)

3. oktober 2028

Studiet fullført (Antatt)

3. oktober 2028

Datoer for studieregistrering

Først innsendt

2. mai 2022

Først innsendt som oppfylte QC-kriteriene

2. mai 2022

Først lagt ut (Faktiske)

5. mai 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere